MedPath

The study to assess the safety of Serioss® (SF Scaffold) in patients.

Not Applicable
Completed
Conditions
Health Condition 1: S821- Fracture of upper end of tibiaHealth Condition 2: S821- Fracture of upper end of tibiaHealth Condition 3: S00-T88- Injury, poisoning and certain other consequences of external causes
Registration Number
CTRI/2021/01/030589
Lead Sponsor
Serigen Mediproducts Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients who have been scheduled for long bone surgery requiring bone void filler. The following clinical /radiological conditions can be included:

Orthopaedic cases: This study will recruit patients with depressed Intra articular fracture of upper end of tibia only requiring bone grafting or use of bone void fillers.

Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects and to comply with the requirements of the entire study.

Subject must be willing and able to give written informed consent prior to any screening procedure.

Subject should not have any known history suggestive of hypersensitivity or allergies to the materials used in the product.

Must be able and willing to provide written informed consent.

Must be willing to or likely to comply with all study requirements.

Exclusion Criteria

Any clinically significant medical condition e.g. active infections, cardiac, diabetes, psychiatric, neurological, pulmonary or immunological conditions etc. which may, in the judgment of the investigator, interfere with the subject’s ability to participate in the study or may interfere with study results.

Subject should not have any clinically significant medical conditions, (including laboratory abnormalities) or disease which could jeopardize subject safety or hamper the results of the study.

Concurrent, serious, uncontrolled infections or current known infection with human immunodeficiency virus (HIV) or active hepatitis B and/or hepatitis C.

Pregnant women

Known sensitivity or allergy to material used in product.

Known allergy to silk fibroin.

History of or current inflammatory joint disease (including RA, gout, reactive arthritis, psoriatic arthritis, seronegative, spondyloarthropathy or Lyme disease).

History of current systemic autoimmune disorder

History of opportunistic infection

History of deep space/tissue infection (e.g., fasciitis, abscess, osteomyelitis) and infected prosthetic joint.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Evaluation of the safety of Serioss® (SF scaffold) for human useTimepoint: At visit 2, Visit 3,Visit 4, Visit 5, Visit 6,Visit 7
Secondary Outcome Measures
NameTimeMethod
To assess effects of Serioss® (SF scaffold), implantation in patients undergoing surgery for bone grafting.Timepoint: From Visit 1 to Visit 7
© Copyright 2025. All Rights Reserved by MedPath